HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by St Clair, E W Search for Related Content PubMed PubMed Citation Articles by St Clair, E W

Infliximab treatment for rheumatic disease: clinical and radiological efficacy

Department of Medicine, Division of Rheumatology, Duke University Medical Center, Durham, NC, USA

Correspondence to:
Correspondence to:
Dr E W St Clair, Box 3874, Duke University Medical Center, Durham, NC 27710, USA;
stcla003{at}mc.duke.edu

ABSTRACT
Infliximab is a chimeric anti-tumour necrosis factor (TNF) monoclonal antibody with high affinity and binding specificity for human TNF. Results from several well designed, controlled clinical trials show repeated infusions of infliximab with concomitant methotrexate (MTX) treatment can reduce the signs and symptoms of rheumatoid arthritis (RA). This combination of infliximab and MTX also slows the radiological progression of joint damage, decreases functional disability, and improves qualify of life. These remarkably positive results have led to the investigation of infliximab treatment for other rheumatic diseases. Recently, controlled studies have shown treatment with infliximab can benefit patients with active spondyloarthropathy. TNF has fast become an important therapeutic target in rheumatology.

Keywords: infliximab; ankylosing spondylitis; tumour necrosis factor

Abbreviations: RA, rheumatoid arthritis; MTX, methotrexate; TNF, tumour necrosis factor ; CRP, C reactive protein

This article has been cited by other articles:

				T. Amano, S. Yamasaki, N. Yagishita, K. Tsuchimochi, H. Shin, K.-i. Kawahara, S. Aratani, H. Fujita, L. Zhang, R. Ikeda, et al. Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy Genes & Dev., October 1, 2003; 17(19): 2436 - 2449. [Abstract] [Full Text] [PDF]